Cytek Biosciences (CTKB) details 2026 shareholder meeting voting outcomes

Rhea-AI Filing Summary

Cytek Biosciences, Inc. reported the results of its 2026 annual meeting of stockholders held on June 10, 2026. Of 129,142,587 common shares outstanding as of April 13, 2026, 111,161,490 were present or represented by proxy, about 86.1% of shares entitled to vote, establishing a strong quorum.

Three director nominees received more votes for than withheld: Vera Imper, Ph.D. (64,769,976 for; 20,723,477 withheld), Glenn P. Muir (79,599,103 for; 5,894,350 withheld) and Ming Yan, Ph.D. (76,741,063 for; 8,752,390 withheld). Two additional matters were also approved, including one that received 84,794,380 votes for and another that received 110,533,253 votes for, each with relatively few votes against.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares outstanding: 129,142,587 shares Shares represented at meeting: 111,161,490 shares Votes for Glenn P. Muir: 79,599,103 votes +2 more

5 metrics

Shares outstanding 129,142,587 shares Common stock outstanding as of April 13, 2026 record date

Shares represented at meeting 111,161,490 shares Present or by proxy at June 10, 2026 annual meeting (~86.1% of eligible)

Votes for Glenn P. Muir 79,599,103 votes Director nominee votes for at 2026 annual meeting

Proposal vote 84,794,380 votes for First non-director proposal with 677,861 against and 21,212 abstentions

Proposal vote 110,533,253 votes for Second non-director proposal with 479,883 against and 148,354 abstentions

Key Terms

annual meeting of stockholders, record date, broker non-votes, emerging growth company, +1 more

5 terms

annual meeting of stockholders financial

"On June 10, 2026, Cytek Biosciences, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”)."

record date financial

"Of the 129,142,587 shares of the Company’s common stock outstanding as of the close of business on the record date of April 13, 2026..."

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

broker non-votes financial

"Nominee ... Votes For ... Votes Withheld ... Broker Non-Votes ... 25,668,037"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Nasdaq Global Select Market financial

"Common Stock, par value $0.001 per share | | CTKB | | Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0001831915 0001831915 2026-06-10 2026-06-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 10, 2026

Cytek Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40632		47-2547526
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

47215 Lakeview Boulevard

Fremont, California 94538

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (877) 922-9835

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CTKB		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 10, 2026, Cytek Biosciences, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). Of the 129,142,587 shares of the Company’s common stock outstanding as of the close of business on the record date of April 13, 2026, 111,161,490 shares were either present at the virtual meeting or represented by proxy, constituting approximately 86.1% of the outstanding shares of common stock entitled to vote. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:

1. Election of Class II Directors. Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following results of voting:

Nominee		Votes For				Votes Withheld				Broker Non-Votes
Vera Imper, Ph.D.			64,769,976				20,723,477				25,668,037
Glenn P. Muir			79,599,103				5,894,350				25,668,037
Ming Yan, Ph.D.			76,741,063				8,752,390				25,668,037

2. Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company’s named executive officers for the year ended December 31, 2025 was approved based on the following results of voting:

Votes For		Votes Against		Abstentions		Broker Non-Votes
84,794,380		677,861		21,212		25,668,037

3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:

Votes For		Votes Against		Abstentions		Broker Non-Votes
110,533,253		479,883		148,354		—

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Cytek Biosciences, Inc.
Date: June 16, 2026				By:		/s/ Wenbin Jiang, Ph.D.
						Wenbin Jiang, Ph.D.
						President and Chief Executive Officer

FAQ

What did Cytek Biosciences (CTKB) report from its 2026 annual meeting?

Cytek Biosciences reported detailed voting results from its 2026 annual stockholder meeting, including quorum and vote counts. Three director nominees received more votes for than withheld, and two additional proposals were approved with strong support and relatively few votes cast against.

How many Cytek Biosciences (CTKB) shares were eligible and represented at the 2026 meeting?

Cytek had 129,142,587 shares eligible to vote as of April 13, 2026. At the June 10, 2026 virtual meeting, 111,161,490 shares were present or represented by proxy, representing about 86.1% of the outstanding common stock entitled to vote.

What were the Cytek Biosciences (CTKB) director nominee vote totals in 2026?

Three director nominees received strong support. Votes for/withheld were: Vera Imper, Ph.D. 64,769,976/20,723,477; Glenn P. Muir 79,599,103/5,894,350; and Ming Yan, Ph.D. 76,741,063/8,752,390, with 25,668,037 broker non-votes on each nominee.

What other proposals did Cytek Biosciences (CTKB) stockholders vote on?

Stockholders voted on two additional proposals. One received 84,794,380 votes for, 677,861 against, and 21,212 abstentions, with 25,668,037 broker non-votes. Another received 110,533,253 votes for, 479,883 against, and 148,354 abstentions, with no broker non-votes reported.

What quorum was achieved at Cytek Biosciences’ 2026 stockholder meeting?

Cytek achieved a high quorum level. Of 129,142,587 common shares outstanding on the April 13, 2026 record date, 111,161,490 shares were present or represented by proxy at the June 10, 2026 meeting, constituting approximately 86.1% of eligible shares.

Who signed the Cytek Biosciences (CTKB) report on the 2026 annual meeting?

The report was signed by Wenbin Jiang, Ph.D., who serves as President and Chief Executive Officer of Cytek Biosciences, Inc. The signature confirms the company’s authorization of the disclosed voting results and related information from the annual meeting.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB